Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation
Version of Record online: 13 DEC 2011
© 2011 Japanese Cancer Association
Volume 103, Issue 2, pages 282–287, February 2012
How to Cite
Horinaka, M., Yoshida, T., Nakata, S., Shiraishi, T., Tomosugi, M., Yoshikawa, S., Wakada, M. and Sakai, T. (2012), Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation. Cancer Science, 103: 282–287. doi: 10.1111/j.1349-7006.2011.02150.x
- Issue online: 1 FEB 2012
- Version of Record online: 13 DEC 2011
- Accepted manuscript online: 12 NOV 2011 11:07AM EST
- (Received September 1, 2011/Revised November 7, 2011/Accepted November 7, 2011/Accepted manuscript online November 12, 2011)
Fig. 1. Dose-dependent effects of aclarubicin (ACR) combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
|CAS_2150_sm_fS1.tif||5946K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.